Abstract:Vascular endothelial growth factor receptor (VEGFR) is a very important receptor tyrosine kinase (RTK) that can induce angiogenesis, increase cell growth and metastasis, reduce apoptosis, alter cytoskeletal function, and affect other biologic changes. Moreover, it is identified to be deregulated in varieties of human cancers. Therefore, VEGFR turn out to be a remarkable target of significant types of anticancer drugs in clinical trials. On the other side, c-Met is the receptor of hepatocyte growth factor (HGF) and a receptor tyrosine kinase. Previous studies have shown that c-Met elicits many different signaling pathways mediating cell proliferation, migration, differentiation, and survival. Furthermore, the correlation between aberrant signaling of the HGF/c-Met pathway and aggressive tumor growth, poor prognosis in cancer patients has been established. Recent reports had shown that c-Met/HGF and VEGFR/VEGF (vascular endothelial growth factor) can act synergistically in the progression of many diseases. They were also found to be over expressed in many human cancers. Thus, in a variety of malignancies, VEGFR and c-Met receptor tyrosine kinases have acted as therapeutic targets. With the development of molecular biology techniques, further understanding of the human tumor disease pathogenesis and interrelated signaling pathways known to tumor cells, using a single target inhibitors have been difficult to achieve the desired therapeutic effect. At this point, with respect to the combination of two inhibitors, a single compound which is able to inhibit both VEGFR and c-Met may put forward the advantage of raising anticancer activity. With the strong interest in these compounds, this review represents a renewal of previous works on the development of dual VEGFR and c-Met small molecule inhibitors as novel anti-cancer agents. Newly collection derivatives have been mainly describing in their biological profiles and chemical structures.

Recent advances and future directions on small molecule VEGFR inhibitors in oncological conditions

Recent updates on potential of VEGFR-2 small-molecule inhibitors as anticancer agents

Recent Development of VEGFR Small Molecule Inhibitors As Anticancer Agents: A Patent Review (2021–2023)

Recent Progress of Small Molecular VEGFR Inhibitors As Anticancer Agents

Anti-Angiogenic Therapy: Strategies to Develop Potent VEGFR-2 Tyrosine Kinase Inhibitors and Future Prospect

Recent Advances in Antiangiogenic Agents with VEGFR As Target

Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy

Recent advances of anti-angiogenic inhibitors targeting VEGF/VEGFR axis

VEGFR-2 Inhibitors and the Therapeutic Applications Thereof: a Patent Review (2012-2016)

Advances In Combination Of Antiangiogenic Agents Targeting Vegf-Binding And Conventional Chemotherapy And Radiation For Cancer Treatment

A Promising Paradigm Shift in Cancer Treatment with FGFR Inhibitors

Recent Advances in the Development of Dual VEGFR and C-Met Small Molecule Inhibitors As Anticancer Drugs

Selective VEGFR inhibitors for anticancer therapeutics in clinical use and clinical trials.

Recent development of multi-target VEGFR-2 inhibitors for the cancer therapy

Research Progress of VEGFR Small Molecule Inhibitors in Ocular Neovascular Diseases

Anti-angiogenic drug discovery: lessons from the past and thoughts for the future

Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy

Targeting FGFRs for Tumor Therapy: Current Status and Novel Strategies

Recent developments in receptor tyrosine kinase inhibitors: A promising mainstay in targeted cancer therapy

Epidermal growth factor receptor inhibitors: a patent review (2010 - present).

VEGF in Signaling and Disease: Beyond Discovery and Development